| 2026-03-16 |
详情>>
内部人交易：
Busch Matthew C.等共交易10笔
|
| 2026-02-13 |
详情>>
股本变动：
变动后总股本53906.77万股
|
| 2026-02-13 |
详情>>
业绩披露：
2025年年报每股收益14.33美元,归母净利润77.11亿美元,同比去年增长88.53%
|
| 2026-02-03 |
财报披露：
美东时间 2026-02-03 盘后发布财报
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益11.86美元,归母净利润63.78亿美元,同比去年增长84.18%
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益5.88美元,归母净利润31.62亿美元,同比去年增长399.53%
|
| 2025-05-02 |
详情>>
业绩披露：
2025年一季报每股收益3.22美元,归母净利润17.30亿美元,同比去年增长1630.97%
|
| 2025-04-09 |
股东大会：
将于2025-05-23召开股东大会
会议内容 ▼▲
- 1.To elect 12 directors to the Board of Directors of Amgen for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Michael V. Drake, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr.,Dr. S. Omar Ishrak, Dr. Tyler Jacks, Dr. Mary E. Klotman, Ms. Ellen J. Kullman, and Ms. Amy E. Miles;
2.To hold an advisory vote to approve our executive compensation;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2025;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
|
| 2025-02-14 |
详情>>
业绩披露：
2024年年报每股收益7.62美元,归母净利润40.90亿美元,同比去年增长-39.11%
|
| 2025-02-14 |
详情>>
业绩披露：
2022年年报每股收益12.18美元,归母净利润65.52亿美元,同比去年增长11.18%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益6.45美元,归母净利润34.63亿美元,同比去年增长-41.8%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益1.18美元,归母净利润6.33亿美元,同比去年增长-85%
|
| 2024-05-03 |
详情>>
业绩披露：
2024年一季报每股收益-0.21美元,归母净利润-1.13亿美元,同比去年增长-103.98%
|
| 2024-04-17 |
股东大会：
将于2024-05-31召开股东大会
会议内容 ▼▲
- 1.To elect 12 directors to the Board of Directors of Amgen for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Michael V. Drake, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. S. Omar Ishrak, Dr. Tyler Jacks, Dr. Mary E. Klotman, Ms. Ellen J. Kullman, and Ms. Amy E. Miles;
2.To hold an advisory vote to approve our executive compensation;
3.To approve our proposed Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which amends our existing Amended and Restated 2009 Equity Incentive Plan to, in part, increase the authorized number of shares issuable under the plan by 31,297,000 shares;
4.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2024;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
|
| 2024-02-14 |
详情>>
业绩披露：
2023年年报每股收益12.56美元,归母净利润67.17亿美元,同比去年增长2.52%
|
| 2023-04-06 |
股东大会：
将于2023-05-19召开股东大会
会议内容 ▼▲
- 1.To elect 13 directors to the Board of Directors of Amgen for a term of office expiring at the 2024 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Michael V. Drake, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. S. Omar Ishrak, Dr. Tyler Jacks, Ms. Ellen J. Kullman, Ms. Amy E. Miles, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams;
2.To hold an advisory vote on the frequency of future stockholder advisory votes to approve executive compensation;
3.To hold an advisory vote to approve our executive compensation;
4.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2023;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
|
| 2023-04-06 |
股东大会：
将于2023-05-19召开股东大会
会议内容 ▼▲
- 1.To elect 13 directors to the Board of Directors of Amgen for a term of office expiring at the 2024 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Michael V. Drake, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. S. Omar Ishrak, Dr. Tyler Jacks, Ms. Ellen J. Kullman, Ms. Amy E. Miles, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams;
2.To hold an advisory vote on the frequency of future stockholder advisory votes to approve executive compensation;
3.To hold an advisory vote to approve our executive compensation;
4.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2023;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
|
| 2022-04-05 |
股东大会：
将于2022-05-17召开股东大会
会议内容 ▼▲
- 1.To elect 12 directors to the Board of Directors of Amgen for a term of office expiring at the 2023 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. S. Omar Ishrak, Dr. Tyler Jacks, Ms. Ellen J. Kullman, Ms. Amy E. Miles, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams;
2.To hold an advisory vote to approve our executive compensation;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2022;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-06 |
股东大会：
将于2021-05-18召开股东大会
会议内容 ▼▲
- 1.To elect 11 directors to the Board of Directors of Amgen for a term of office expiring at the 2022 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. Tyler Jacks, Ms. Ellen J. Kullman, Ms. Amy E. Miles, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams;
2.To hold an advisory vote to approve our executive compensation;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2021;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
|
| 2020-04-07 |
股东大会：
将于2020-05-19召开股东大会
会议内容 ▼▲
- 1.To elect 11 directors to the Board of Directors of Amgen for a term of office expiring at the 2021 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Fred Hassan, Mr. Charles M. Holley, Jr., Dr. Tyler Jacks, Ms. Ellen J. Kullman, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams;
2.To hold an advisory vote to approve our executive compensation;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2020;
4.To consider one stockholder proposal, if properly presented at the Annual Meeting;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
|
| 2020-03-04 |
除权日：
美东时间 2020-05-15 每股派息1.60美元
|
| 2019-12-11 |
除权日：
美东时间 2020-02-13 每股派息1.60美元
|
| 2019-10-22 |
除权日：
美东时间 2019-11-14 每股派息1.45美元
|
| 2019-08-02 |
除权日：
美东时间 2019-08-14 每股派息1.45美元
|
| 2019-04-08 |
股东大会：
将于2019-05-21召开股东大会
会议内容 ▼▲
- 1.To elect 12 directors to the Board of Directors of Amgen for a term of office expiring at the 2020 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Fred Hassan, Dr. Rebecca M. Henderson, Mr. Charles M. Holley, Jr., Dr. Tyler Jacks, Ms. Ellen J. Kullman, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams;
2.To hold an advisory vote to approve our executive compensation;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2019;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment thereof.
|
| 2019-03-07 |
除权日：
美东时间 2019-05-16 每股派息1.45美元
|
| 2018-12-07 |
除权日：
美东时间 2019-02-14 每股派息1.45美元
|
| 2018-10-23 |
除权日：
美东时间 2018-11-15 每股派息1.32美元
|
| 2018-07-31 |
除权日：
美东时间 2018-08-16 每股派息1.32美元
|
| 2018-04-11 |
股东大会：
将于2018-05-22召开股东大会
会议内容 ▼▲
- 1.To elect 13 directors to the Board of Directors of Amgen for a term of office expiring at the 2019 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Fred Hassan, Dr. Rebecca M. Henderson, Mr. Frank C. Herringer, Mr. Charles M. Holley, Jr., Dr. Tyler Jacks, Ms. Ellen J. Kullman, Dr. Ronald D. Sugar and Dr. R. Sanders Williams;
2.To hold an advisory vote to approve our executive compensation;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018;
4.To consider one stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation, if properly presented at the meeting;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2018-03-07 |
除权日：
美东时间 2018-05-16 每股派息1.32美元
|
| 2017-12-12 |
除权日：
美东时间 2018-02-14 每股派息1.32美元
|
| 2017-10-24 |
除权日：
美东时间 2017-11-16 每股派息1.15美元
|
| 2017-07-28 |
除权日：
美东时间 2017-08-15 每股派息1.15美元
|
| 2017-04-06 |
股东大会：
将于2017-05-19召开股东大会
会议内容 ▼▲
- 1.To elect 13 directors to the Board of Directors of Amgen for a term of office expiring at the 2018 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. David Baltimore, Mr. Robert A. Bradway, Mr. Francois de Carbonnel, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Fred Hassan, Dr. Rebecca M. Henderson, Mr. Frank C. Herringer, Mr. Charles M. Holley, Jr., Dr. Tyler Jacks, Ms. Ellen J. Kullman, Dr. Ronald D. Sugar and Dr. R. Sanders Williams;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2017;
3.To hold an advisory vote to approve our executive compensation;
4.To hold an advisory vote on the frequency of future stockholder advisory votes to approve executive compensation;
5.To consider one stockholder proposal to adopt majority votes cast standard for matters presented by stockholders described in the proxy statement, if properly presented at the meeting;
6.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2017-03-07 |
除权日：
美东时间 2017-05-15 每股派息1.15美元
|
| 2016-12-20 |
除权日：
美东时间 2017-02-13 每股派息1.15美元
|
| 2016-10-14 |
除权日：
美东时间 2016-11-14 每股派息1.00美元
|
| 2016-07-22 |
除权日：
美东时间 2016-08-15 每股派息1.00美元
|
| 2016-04-07 |
股东大会：
将于2016-05-19召开股东大会
会议内容 ▼▲
- 1.To elect 13 directors to the Board of Directors of Amgen for a term of office expiring at the 2017 annual meeting of stockholders. The nominees for election to the Board of Directors are Dr. David Baltimore, Mr. Frank J. Biondi, Jr., Mr. Robert A. Bradway, Mr. Franois de Carbonnel, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Fred Hassan, Dr. Rebecca M. Henderson, Mr. Frank C. Herringer, Dr. Tyler Jacks, Ms. Judith C. Pelham, Dr. Ronald D. Sugar and Dr. R. Sanders Williams;
2.To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2016;
3.To hold an advisory vote to approve our executive compensation;
4.To consider one stockholder proposal to change the voting standard applicable to non-binding proposals submitted by stockholders, if properly presented;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof.
|
| 2016-03-02 |
除权日：
美东时间 2016-05-13 每股派息1.00美元
|
| 2015-12-15 |
除权日：
美东时间 2016-02-11 每股派息1.00美元
|
| 2015-10-14 |
除权日：
美东时间 2015-11-12 每股派息0.79美元
|
| 2015-07-28 |
除权日：
美东时间 2015-08-13 每股派息0.79美元
|
| 2015-03-04 |
除权日：
美东时间 2015-05-12 每股派息0.79美元
|
| 2014-12-17 |
除权日：
美东时间 2015-02-10 每股派息0.79美元
|
| 2014-10-17 |
除权日：
美东时间 2014-11-10 每股派息0.61美元
|
| 2014-07-25 |
除权日：
美东时间 2014-08-12 每股派息0.61美元
|
| 2014-03-05 |
除权日：
美东时间 2014-05-13 每股派息0.61美元
|
| 2013-12-13 |
除权日：
美东时间 2014-02-11 每股派息0.61美元
|
| 2013-10-16 |
除权日：
美东时间 2013-11-12 每股派息0.47美元
|
| 2013-07-26 |
除权日：
美东时间 2013-08-14 每股派息0.47美元
|
| 2013-03-06 |
除权日：
美东时间 2013-05-14 每股派息0.47美元
|
| 2012-12-13 |
除权日：
美东时间 2013-02-11 每股派息0.47美元
|
| 2012-10-10 |
除权日：
美东时间 2012-11-13 每股派息0.36美元
|
| 2012-07-19 |
除权日：
美东时间 2012-08-14 每股派息0.36美元
|
| 2012-03-15 |
除权日：
美东时间 2012-05-14 每股派息0.36美元
|
| 2011-12-15 |
除权日：
美东时间 2012-02-13 每股派息0.36美元
|
| 2011-10-13 |
除权日：
美东时间 2011-11-15 每股派息0.28美元
|
| 2011-07-28 |
除权日：
美东时间 2011-08-16 每股派息0.28美元
|